

# Key Information Document

## Bluebox Precision Medicine Fund

### A Sub-Fund of BlueBox Funds

#### I (EUR) acc.

Asset  
Management

bluebox

## ➤ Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## ➤ Product

<b>Name:</b>	Bluebox Precision Medicine Fund I (EUR) acc.
<b>ISIN:</b>	LU2519373380
<b>PRIIP Manufacturer:</b>	Carne Global Fund Managers (Luxembourg) S.A.
<b>PRIIP Manufacturer Website:</b>	<a href="https://www.carnegroup.com">https://www.carnegroup.com</a>
<b>Telephone:</b>	+352 26 73 23 54

The Commission de Surveillance du Secteur Financier is responsible for supervising Carne Global Fund Managers (Luxembourg) S.A. in relation to this Key Information Document.

This PRIIP is authorised in Luxembourg.

Carne Global Fund Managers (Luxembourg) S.A. (the "Manager") is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier.

The key information document is accurate as at 19 February 2026.

**You are about to purchase a product that is not simple and may be difficult to understand.**

## ➤ What is this product?

**Type:** This product is a UCITS.

**Term:** No fixed term.

**Objectives:** The main objective of the Fund is to seek to maximise total return. The Fund invests globally with at least 85% of its total assets in the equity securities of companies whose predominant economic activity is in the pharmaceuticals, biotechnology and life science sectors. The remaining 15% of the total assets of the BlueBox Precision Medicine Fund may be invested in equity securities of companies or issuers of any size in any sector of the economy globally and whose predominant economic activity is not in the pharmaceuticals, biotechnology and life science sectors. The overall investment strategy of the BlueBox Precision Medicine Fund is to seek out companies that will create value for the Shareholders from precision medicine: the multi-year trend of increasingly precise and targeted drug development in the pharmaceutical and biotechnology industries. The BlueBox Precision Medicine Fund will typically hold 25 to 45 positions. The holding periods are expected to be generally long (multiple years) and turnover low, although at times the BlueBox Precision Medicine Fund may utilise shorter holding periods if value is realised more quickly or unexpected events occur. The geographic focus of the strategy is global. The sector focus is predominantly pharmaceuticals, biotechnology and life science, however the BlueBox Precision Medicine Fund may also acquire shares in companies classified in other sectors with a strong pharmaceutical, biotechnology or life science element to their business. Holdings will be primarily of publicly listed companies, typically with a market capitalisation of about \$1bn or more, but the BlueBox Precision Medicine Fund will take part in initial public offerings (where the market cap may be significantly below \$1bn at listing) and it may occasionally invest in private companies where an initial public offering is strongly expected to follow within 18 months or so. The BlueBox Precision Medicine Fund may not acquire shares carrying voting rights which should enable it to exercise significant influence over the management of an issuing body. The Fund promotes environmental, social and governance (ESG) characteristics and is thus classified as a financial product falling within the scope of Article 8 of the SFDR. For details of ESG approach, please refer to [www.blueboxfunds.com](http://www.blueboxfunds.com). The BlueBox Precision Medicine Fund will not invest in FDIs, nor enter into any securities financing transaction within the meaning of the SFT Regulations. Should the BlueBox Precision Medicine Fund wish at a later stage to enter into any of these transactions, the Prospectus will be updated accordingly. It is currently not contemplated for the BlueBox Precision Medicine Fund to invest in Russian equities or equity related securities. Purchase and sale of shares in the Fund can be made on each Business Day. The Fund is active and managed without any reference to a benchmark. The Management Company has discretion over the composition of its portfolio subject to this objective and investment policy.

**Recommendation:** this Fund may not be appropriate for investors who plan to withdraw their money within five years. The Fund does not intend to declare or make distributions.

**Intended retail investor:** Investment in the BlueBox Precision Medicine Fund is suitable for all investors (retail, professional clients and eligible counterparties) seeking medium to long term capital gains through investments in global equities and specifically in the pharmaceuticals, biotechnology and life science sectors. Investors should understand the risks involved in an investment of this kind, as those mentioned in the Risk Factors Annex of the Prospectus and should be able to tolerate the levels of volatility associated with equities in the pharmaceuticals, biotechnology and life science sectors and eventually accept potential losses due to market fluctuations. The BlueBox Precision Medicine Fund may not be compatible for investors outside the target market or those that are not able to bear all losses with respect to their investment. Classes of the BlueBox Precision Medicine Fund are eligible for all distribution channels (e.g., investment advice, portfolio management, non-advised sales and pure execution services).

**Depository:** The Fund's assets are held through its Depository, which is Northern Trust Global Services SE.

**Distribution type:** The product is accumulating.

## ➤ What are the risks and what could I get in return?

### Risk indicator

Lower risk

Higher risk



1	2	3	4	5	6	7
---	---	---	---	---	---	---



The risk indicator assumes you keep the product for 5 years.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class.

### Performance scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and a suitable proxy over the last 10 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

Example investment: EUR 10,000		1 year	5 years
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress scenario	What you might get back after costs	EUR 2,820	EUR 1,920
	Average return each year	-71.82%	-28.11%
Unfavourable scenario <sup>1</sup>	What you might get back after costs	EUR 7,860	EUR 10,900
	Average return each year	-21.43%	1.75%
Moderate scenario <sup>2</sup>	What you might get back after costs	EUR 10,300	EUR 14,000
	Average return each year	3.00%	6.97%
Favourable scenario <sup>3</sup>	What you might get back after costs	EUR 13,710	EUR 17,770
	Average return each year	37.08%	12.18%

<sup>1</sup>This type of scenario occurred for an investment from 10/2018 to 10/2023.

<sup>2</sup>This type of scenario occurred for an investment from 05/2017 to 05/2022.

<sup>3</sup>This type of scenario occurred for an investment from 12/2016 to 12/2021.

## ➤ What happens if Carne Global Fund Managers (Luxembourg) S.A. is unable to pay out?

The assets and liabilities of the Sub-fund are segregated from those of the other sub-funds and from those of the manufacturer or the custodian. If the UCITS is not able to pay you out what is due, you may lose your entire investment. No investor guarantee nor compensation scheme is foreseen in that eventuality.

## ➤ What are the costs ?

### Costs over time

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return)
- For the other holding periods we have assumed the product performs as shown in the moderate scenario
- EUR 10,000 is invested

Example Investment: EUR 10,000	If you cash in after 1 year	If you cash in after 5 years
<b>Total costs</b>	EUR 651	EUR 1,807
<b>Annual cost impact(*)</b>	6.51%	2.63%

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 9.60% before costs and 6.97% after costs.

### Composition of costs

The table below shows the impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period and the meaning of the different cost categories.

The table shows the impact on return per year		If you exit after 1 year	
<b>One-off costs upon entry or exit</b>	Entry costs	<b>Up to 5.00%</b> This is a maximum figure, only applied at the request of a distribution platform. No entry cost has ever been applied to this share class. In some cases you will be charged less, or nothing. Please refer to your financial advisor or the distributor for the actual charges.	<b>Up to EUR 500</b>
	Exit costs	We do not charge an exit fee for this product.	EUR 0
<b>Ongoing costs taken each year</b>	Management fees and other administrative or operating costs	1.5% of the value of your investment per year. This is an estimate based on actual costs over the last year.	EUR 150
	Transaction costs	0.01% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	EUR 1
<b>Incidental costs taken under specific conditions</b>	Performance fees and carried interest	There is no performance fee for this product.	EUR 0

## ➤ How long should I hold it and can I take my money out early?

**The recommended minimum holding period: 5 years.**

This should be considered a medium to long term investment, however there is no minimum term, nor are there any redemption restrictions.

## ➤ How can I complain?

If you have any complaints about the product, the conduct of the manufacturer or the person advising on the product, complaints can be lodged via the following methods:

E-mail: [complaints@carnegroup.com](mailto:complaints@carnegroup.com),

Mail: Carne Global Fund Managers (Luxembourg) S.A. 3, Rue Jean Piret, L-2350 Luxembourg.

## ➤ Other relevant information

Alongside this document, we invite you to carefully consult the Prospectus on our website.

This share class launched in 2020. Previous monthly performance scenario calculations can be found at <https://www.blueboxfunds.com/>. Please note that past performance is not indicative of future performance. It cannot provide a guarantee of returns that you will receive in the future.

Additional information for investors in Switzerland: The representative in Switzerland is REYL & Cie Ltd, Rue du Rhône 4, CH-1204 Geneva. The prospectus, the Key Information Document, the articles of association as well as the annual and semi-annual reports may be obtained free of charge from the representative. Current share prices are available on [www.fundinfo.com](http://www.fundinfo.com). The paying agent in Switzerland is REYL & Cie Ltd, Rue du Rhône 4, CH-1204 Geneva.